SK284199B6 - Triazolo[4,5-d]pyrimidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie - Google Patents

Triazolo[4,5-d]pyrimidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie Download PDF

Info

Publication number
SK284199B6
SK284199B6 SK1881-99A SK188199A SK284199B6 SK 284199 B6 SK284199 B6 SK 284199B6 SK 188199 A SK188199 A SK 188199A SK 284199 B6 SK284199 B6 SK 284199B6
Authority
SK
Slovakia
Prior art keywords
triazolo
pyrimidin
amino
propylthio
cyclopentane
Prior art date
Application number
SK1881-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK188199A3 (en
Inventor
Simon Guile
Anthony Ingall
Brian Springthorpe
Paul Willis
Original Assignee
Astra Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284199(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9702773A external-priority patent/SE9702773D0/xx
Priority claimed from SE9702775A external-priority patent/SE9702775D0/xx
Application filed by Astra Pharmaceuticals Ltd. filed Critical Astra Pharmaceuticals Ltd.
Publication of SK188199A3 publication Critical patent/SK188199A3/sk
Publication of SK284199B6 publication Critical patent/SK284199B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SK1881-99A 1997-07-22 1998-07-15 Triazolo[4,5-d]pyrimidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie SK284199B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702773A SE9702773D0 (sv) 1997-07-22 1997-07-22 Novel compounds
SE9702775A SE9702775D0 (sv) 1997-07-22 1997-07-22 Novel compounds
PCT/SE1998/001393 WO1999005143A1 (fr) 1997-07-22 1998-07-15 Nouveaux composes

Publications (2)

Publication Number Publication Date
SK188199A3 SK188199A3 (en) 2000-10-09
SK284199B6 true SK284199B6 (sk) 2004-10-05

Family

ID=26663042

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1881-99A SK284199B6 (sk) 1997-07-22 1998-07-15 Triazolo[4,5-d]pyrimidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie

Country Status (31)

Country Link
EP (1) EP0996621B1 (fr)
JP (1) JP4187406B2 (fr)
KR (2) KR20050084540A (fr)
CN (1) CN1154650C (fr)
AR (2) AR017014A1 (fr)
AT (1) ATE251161T1 (fr)
AU (1) AU745381B2 (fr)
BR (1) BR9810802B1 (fr)
CA (1) CA2296665C (fr)
CZ (1) CZ302629B6 (fr)
DE (1) DE69818668T2 (fr)
DK (1) DK0996621T3 (fr)
EE (1) EE04193B1 (fr)
EG (1) EG24412A (fr)
ES (1) ES2207846T3 (fr)
HK (1) HK1026421A1 (fr)
HU (1) HU230074B1 (fr)
IL (2) IL133959A0 (fr)
IS (1) IS2236B (fr)
MY (1) MY123196A (fr)
NO (1) NO315854B1 (fr)
NZ (1) NZ502381A (fr)
PL (1) PL200325B1 (fr)
PT (1) PT996621E (fr)
RU (1) RU2225407C2 (fr)
SA (1) SA98190487B1 (fr)
SK (1) SK284199B6 (fr)
TR (1) TR200000197T2 (fr)
TW (1) TW530058B (fr)
UA (1) UA66801C2 (fr)
WO (1) WO1999005143A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013487D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Novel process
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
AR028110A1 (es) 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
SE0004099D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
SE0004098D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
ATE469157T1 (de) 2003-10-21 2010-06-15 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
CA2668180A1 (fr) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Derives de triazolopyrimidine convenant comme antagonistes du recepteur p2y12 de l'adp
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
AU2009292269B2 (en) 2008-09-09 2012-11-01 Astrazeneca Ab A process for preparing [1S- [1-alpha, 2-alpha, 3-beta (1S*, 2R*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3H-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
EP2361242B1 (fr) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Inhibiteurs de l'oxydase et leur utilisation
WO2010084160A1 (fr) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2305376A1 (fr) 2009-09-23 2011-04-06 Lonza Ltd. Procédé et catalyseur pour l'hydrogénation catalytique de composés de nitro aromatiques et hétéro-aromatiques
CA2812683C (fr) 2009-09-25 2017-10-10 Oryzon Genomics S.A. Inhibiteurs de demethylase-1 specifique de la lysine et leur utilisation
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
KR20120123659A (ko) 2009-12-03 2012-11-09 아스트라제네카 아베 트리아졸로［4,5-ｄ］피리미딘 혈소판 응집 억제제의 공결정
ES2548845T3 (es) 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
EP2536695A1 (fr) 2010-02-16 2012-12-26 Actavis Group Ptc Ehf Procédés améliorés pour préparer un intermédiaire de ticagrelor, la 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
WO2011106574A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs destinés à une utilisation antivirale
WO2011106106A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour lutter contre les maladies et troubles associés à l'hepadnaviridae
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
EP2560939A2 (fr) 2010-04-20 2013-02-27 Actavis Group Ptc Ehf Nouveau procédé de préparation de dérivés de phénylcyclopropylamine par utilisation de nouveaux intermédiaires
RU2013103794A (ru) 2010-06-30 2014-08-10 Актавис Груп Птс Ехф Новые способы получения производных фенилциклопропиламина и их применение для получения тикагрелора
RU2611437C2 (ru) 2010-07-29 2017-02-22 Оризон Дженомикс С.А. Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине
EP2598480B1 (fr) * 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (fr) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Procédés améliorés de préparation de (3ar,4s,6r,6as)-6-amino-2,2-diméthyltétrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol pur et son matériau de départ clé
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
CA2859743A1 (fr) 2010-12-20 2012-06-28 Actavis Group Ptc Ehf Nouveaux procedes de preparation de derives triazolo[4,5-d]pyrimidine et de leurs intermediaires
WO2012107498A1 (fr) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Inhibiteurs de lysine diméthylase pour des troubles myéloprolifératifs
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CA2836394A1 (fr) 2011-06-01 2012-12-06 Astrazeneca Ab Nouveaux co-cristaux de ticagrelor
AU2012270017A1 (en) 2011-06-15 2014-01-16 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ES2665546T3 (es) * 2011-10-27 2018-04-26 Lek Pharmaceuticals D.D. Síntesis de compuestos de triazolopirimidina
EP2589587A1 (fr) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthèse de cyclopropanes à substitution azote
AU2012343928A1 (en) 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
CN103965198A (zh) * 2013-02-05 2014-08-06 郝聪梅 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法
CN103183679A (zh) * 2013-03-20 2013-07-03 西藏海思科药业集团股份有限公司 抗凝血化合物及其应用
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP3003276A1 (fr) 2013-05-29 2016-04-13 ratiopharm GmbH Forme posologique pharmaceutique solide
WO2014206187A1 (fr) * 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Procédé de préparation du ticagrelor et de ses intermédiaires
CN103588751B (zh) * 2013-11-07 2014-12-17 苏州明锐医药科技有限公司 替格瑞洛中间体的制备方法
WO2015162630A1 (fr) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Nouveaux procédés de préparation de triazolo[4,5-d]-pyrimidines, dont le ticagrelor, via de nouveaux intermédiaires et une nouvelle voie de synthèse
EP3157907B1 (fr) 2014-06-18 2018-08-29 Flamma S.P.A. Procédé pour la préparation de composés de triazolo[4,5-d]pyrimidine cyclopentane
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
ES2901197T3 (es) 2016-03-22 2022-03-21 Merck Sharp & Dohme Moduladores alostéricos de los receptores nicotínicos de la acetilcolina
WO2018167447A1 (fr) 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants
CN107141298A (zh) * 2017-07-24 2017-09-08 苏州信恩医药科技有限公司 一种替格瑞洛的合成方法
TWI641327B (zh) * 2017-09-30 2018-11-21 双邦實業股份有限公司 Socks that are comfortable and comfortable to wear
EP3527571A1 (fr) * 2018-02-14 2019-08-21 Université de Liège Dérivés de pyrimidine pour la prévention et le traitement d'infections bactériennes
WO2023213198A1 (fr) * 2022-05-04 2023-11-09 华东师范大学 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant
CN114805367B (zh) * 2022-05-24 2023-04-07 郑州大学 一种三氮唑并嘧啶类衍生物及其制备方法和应用
CN115710275B (zh) * 2022-11-21 2024-02-02 河南中医药大学 一种嘧啶-tcp类化合物、制备方法和医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
PL182680B1 (pl) * 1995-07-11 2002-02-28 Astrazeneca Ab Nowe inhibitory skupiania się płytek krwi
AU5501598A (en) * 1996-12-20 1998-07-17 Astra Pharmaceuticals Limited Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments

Also Published As

Publication number Publication date
NZ502381A (en) 2001-12-21
KR20050084540A (ko) 2005-08-26
BR9810802B1 (pt) 2010-10-19
PT996621E (pt) 2004-02-27
HK1026421A1 (en) 2000-12-15
AU745381B2 (en) 2002-03-21
KR20010022083A (ko) 2001-03-15
SK188199A3 (en) 2000-10-09
EG24412A (en) 2009-05-25
HU230074B1 (hu) 2015-06-29
IS2236B (is) 2007-05-15
WO1999005143A1 (fr) 1999-02-04
JP4187406B2 (ja) 2008-11-26
TR200000197T2 (tr) 2000-06-21
HUP0004333A3 (en) 2001-11-28
EE04193B1 (et) 2003-12-15
JP2001510842A (ja) 2001-08-07
CA2296665A1 (fr) 1999-02-04
HUP0004333A2 (hu) 2001-04-28
DE69818668T2 (de) 2004-08-12
CN1270590A (zh) 2000-10-18
UA66801C2 (uk) 2004-06-15
EP0996621A1 (fr) 2000-05-03
CN1154650C (zh) 2004-06-23
IS5354A (is) 2000-01-20
RU2225407C2 (ru) 2004-03-10
IL133959A (en) 2007-10-31
NO20000312D0 (no) 2000-01-21
AR017014A1 (es) 2001-08-22
PL338516A1 (en) 2000-11-06
EE200000044A (et) 2000-10-16
IL133959A0 (en) 2001-04-30
AR077553A2 (es) 2011-09-07
BR9810802A (pt) 2000-09-12
MY123196A (en) 2006-05-31
NO315854B1 (no) 2003-11-03
CZ302629B6 (cs) 2011-08-10
DE69818668D1 (de) 2003-11-06
TW530058B (en) 2003-05-01
ES2207846T3 (es) 2004-06-01
SA98190487B1 (ar) 2006-08-20
KR100535837B1 (ko) 2006-01-12
NO20000312L (no) 2000-03-21
ATE251161T1 (de) 2003-10-15
CA2296665C (fr) 2008-06-10
PL200325B1 (pl) 2008-12-31
CZ2000233A3 (cs) 2000-07-12
DK0996621T3 (da) 2004-02-02
AU8370698A (en) 1999-02-16
EP0996621B1 (fr) 2003-10-01

Similar Documents

Publication Publication Date Title
SK284199B6 (sk) Triazolo[4,5-d]pyrimidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
US6251910B1 (en) 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
US7250419B2 (en) Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
US6156756A (en) Triazolo [4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation
DE69905451T2 (de) Neue triazolo(4,5d) pyrimidinverbindungen
MXPA00000685A (en) Novel compounds
CZ2000231A3 (cs) Nové sloučeniny

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180715